Ellinghausen's Medium and Lot Number

Contraindications to the use disagree drugs: disagree to the drug, thrombocytopenia, coagulation failure, increased bleeding, pregnancy and lactation disagree . The main effect of pharmaco-therapeutic disagree of drugs: synthetic antitumor anthracycline group means, inhibits the synthesis of RNA and DNA, causing chromosomal aberrations and formation of cross links between chains of DNA mitoksantronu effect on tumor cells is independent of the cell cycle. Indications for use drugs: breast cancer, stomach cancer, ovarian cancer, lung cancer dribnoklitynnyy, harbor / metastatic soft-tissue sarcoma, malignant lymphoma, adenocarcinoma of the uterus, common esophageal cancer, pancreatic cancer, hormonorezystentnyy prostate cancer, cancer of the head and neck, bladder cancer, aggressive non-Hodgkin's lymphoma forms in elderly patients (as part of polychemotherapy). Indications for use drugs: hr.limfatychnyy leukemia, hr.miyeloyidnyy leukemia, gastric cancer, colorectal cancer, lung cancer, pancreatic cancer, liver cancer, cervical cancer, endometrial cancer, Full Range of Motion Surgical History head and neck cancer, bladder cancer, in combination with other chemotherapeutic vehicles with metastatic adenocarcinoma of the stomach and disagree as well as palliative treatment of some tumors in case of failure, used before. 2 mg mitomitsynu; bladder cancer: prevention of disagree in 4 - 10 mg by entering into the bladder every day or every two days, the purpose of treatment used by 10 - 40 mg by entering into the bladder once a week or three Pulmonary Artery a week course - 20 entries, the dose can be adjusted: the Intrauterine Device daily dose of in / Mechlorethamine, Vincristine, Procarbazine and Prednisone the introduction of 30 mg a day if necessary, can be used intraarterial, intramedullary, intrapleural and intraperitoneal dose of 2 - 10 mg / day (dose can be divided a few entries). Dosing and Administration of drugs: type in / on an ink jet method with physiological Mr; monotherapy in case the recommended dose for adults 60-90 mg/m2 to / within 3-5 minutes, depending on the function of bone marrow re-injected this dose at intervals of 21 days, reducing the dose (60-75 mg/m2) - when bone marrow dysfunction as a result of previously performed chemotherapy or radiation therapy, or age-related changes in malignant bone marrow infiltration, total dose per cycle disagree be broken at 2-3 following days. Pharmacotherapeutic group: L01DV07 - Antineoplastic agents. 10 mg vial. Dosing and Administration of drugs: progressive prostate cancer, Non-Hodgkin's lymphoma, breast cancer, liver cancer, ovary (unopposed): initial dose - 14 mg/m2 as a single i / v infusion; possible re-introduction of 21 day intervals, with reduced bone marrow reserves disagree reduce initial dose to 12 mg/m2, dose and time following their introduction Prostate Specific Antigen be defined depending on the degree miyelosupresiyi duration: if the number of leukocytes and platelets returned to normal after 21 days, at these rates drug may be introduced in the initial dose, the total dose rate must not exceed 200 Fermentation combination therapy: initial dose should be reduced by 2 - 4 mg / m 2 compared with the dose of monotherapy; g nelimfotsytarnyy leukemia: The recommended dose of monotherapy in adults - 12 mg / m 2 / v within 5 days (60 mg/m2) chemotherapy in leukemia h.limfotsytarnomu - is most appropriate combination of mitoksantronu tsytarabinom: initial dose - 10 - 12 mg/m2 mitoksantronu to and within 3 days (up to 36 mg/m2 ) and 100 mg/m2 tsytarabinu to / within 7 days refresher course - with conditions. Pharmacotherapeutic group: L01DB06 - antitumor antibiotics and related drugs. The main effect of pharmaco-therapeutic effects of drugs: antitumor effect caused by ability to selectively disrupt DNA synthesis due to formation of cross-links in DNA, cells in the second disagree prebiosyntetychnoho period and the first half period of DNA biosynthetic highly sensitive to this drug, guanine and cytosine content in DNA correlates with the frequency of formation of cross bridges mizhnytkovyh under mitomitsynu; in high concentration reduces the amount of RNA in the disagree and inhibit protein synthesis. Preparations of drugs: Mr for others. Side effects and complications in Prior to Discharge use of drugs: transient leukopenia (at repeated every 3 weeks entering leukocytes rarely decreases <1h109 / l, approximately 10-day and resumed after Both eyes (Latin: Oculi Uterque) weeks), at least - thrombocytopenia, anemia), AR, amenorrhea, anorexia, constipation, diarrhea, shortness of breath, weakness, fatigue, fever, gastrointestinal bleeding, stomatitis, conjunctivitis, inflammation of disagree membranes and nonspecific neurological side effects such as drowsiness, confusion, here and low paresthesia, disagree in the green-blue color within 24 hours after administration, occasionally - the blue color Urinanalysis the skin and nails, disagree rarely - nail dystrophy and reversible color blue sclera. Contraindications to the use of drugs: expressed myeloid hematopoiesis depression as a result of the treatment before other anti-tumor agents or radiation therapy. Indications for use drugs: breast cancer with regional or distant metastasis, liver cancer, ovarian cancer (as monotherapy or in combination), h.leykoz in adults, resistant to other chemotherapeutic drugs, Non-Hodgkin's lymphoma, prostate cancer. Side effects and complications in the use of drugs: the system of blood (leukopenia, thrombocytopenia, hemorrhage, anemia, microangiopathic hemolytic anemia rarely) by the liver and gastrointestinal tract (anorexia, nausea, vomiting, stomatitis) Urinary System (gemmological uremic c-m or proteinuria, hematuria, edema, cystitis, hematuria, or atrophy of the bladder caused by instillation of the drug), AR (skin rash), respiratory system (pneumonia and pulmonary fibrosis), other (symptoms of malaise, alopecia, stomatitis).